• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ARCT

    Arcturus Therapeutics Holdings Inc.

    Subscribe to $ARCT
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

    IPO Year: 2013

    Exchange: NASDAQ

    Website: arcturusrx.com

    Peers

    $CVAC

    Recent Analyst Ratings for Arcturus Therapeutics Holdings Inc.

    DatePrice TargetRatingAnalyst
    1/28/2025$41.00Buy
    BTIG Research
    8/12/2024$70.00Outperform
    Leerink Partners
    12/13/2023$90.00Buy
    Canaccord Genuity
    7/24/2023$71.00Outperform
    William Blair
    5/11/2023$19.00 → $51.00Neutral → Buy
    H.C. Wainwright
    11/14/2022$35.00Overweight
    Wells Fargo
    11/10/2022$18.00Neutral → Underperform
    Robert W. Baird
    11/3/2022$22.00 → $35.00Neutral → Buy
    Citigroup
    11/2/2022$16.00 → $25.00Underweight → Equal Weight
    Barclays
    8/10/2022Mkt Perform → Underperform
    Raymond James
    See more ratings

    Arcturus Therapeutics Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun

      4/22/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1 subtype contained in the vaccine. This designation recognizes the potential of ARCT-2304 as an innovative approach to address unmet medical needs for the prevention of disease caused by pandemic influ

      4/10/25 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

      Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updat

      3/6/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Leerink's Global Healthcare Conference 2025 in Miami, on Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time. Webcast link can be found under Investor Relations/Events section of Arcturus' website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines company with

      3/5/25 4:30:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 6, 2025. Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call Thursday, March 6, 2025 @4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURU

      2/24/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

      - KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials WALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL ((ASX: CSL, OTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (NASDAQ:ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOST

      2/14/25 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

      - KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials Global biotechnology leader CSL ((ASX: CSL, OTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (NASDAQ:ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19. Th

      2/14/25 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea

      2/4/25 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

      Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of "KOSTAIVE® for Intramuscular Injection," a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan. Meiji Seika Pharma and ARCALIS Co., Ltd. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu) have been working together to establish an infrastructure that enables the integrated production of pharmaceuticals, from active ingredients to final products, within Japan. With t

      1/31/25 3:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found under Investor Relations/Events section of Arcturus' website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines

      1/30/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcturus Therapeutics Holdings Inc. Financials

    Live finance-specific insights

    See more
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun

      4/22/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

      Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updat

      3/6/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 6, 2025. Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call Thursday, March 6, 2025 @4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURU

      2/24/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

      Cystic Fibrosis and OTC Deficiency Phase 2 studies on track for POC data in first half of 2025 $25 Million commercial milestone achieved with first sale of KOSTAIVE® in Japan KOSTAIVE® European CHMP opinion expected December Positive results from multiple Phase 3 studies support KOSTAIVE® U.S. BLA filing in H1 2025 Superior 12-month durability results from Phase 3 study of KOSTAIVE® published in The Lancet Infectious Diseases Positive Phase 3 results showed KOSTAIVE® XBB.1.5. met all four primary study objectives and key secondary objectives Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messe

      11/7/24 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2024 after the market close on Thursday, November 7 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 7, 2024. Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call Thursday, November 7, 2024 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference I

      10/31/24 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

      IND submitted for Phase 2 trial of ARCT-032 targeting cystic fibrosis (CF) ARCT-810 (OTC deficiency) Phase 2 interim data on track for Q4 Kostaive® on track for Q4 commercial launch in Japan Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided corporate updates. "We are pleased to remain on track for our first commercial product launch of Ko

      8/5/24 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2024 after the market close on Monday, August 5 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 5, 2024. Arcturus Therapeutics Second Quarter 2024 Earnings Conference Call Monday, August 5, 2024 @ 4:30 p.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13747924 Web

      7/18/24 7:30:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

      Commercial manufacture of Kostaive® on track for delivery of initial 4 million doses in Q3 Kostaive® European Marketing Authorization Application approval decision expected Q3 Multiple Kostaive® Phase 3 trials further demonstrate breadth and durability of STARR® vaccine platform ARCT-2138 (LUNAR-FLU) Phase 1 topline immunogenicity and safety data, anticipated in Q3 ARCT-810 (LUNAR-OTC) Phase 2 and ARCT-032 (LUNAR-CF) Phase 1b interim data and update to be provided on July 1st JP Morgan engaged to monetize investment in ARCALIS JV in Japan Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messe

      5/8/24 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024. Arcturus Therapeutics First Quarter 2024 Earnings Conference Call Wednesday, May 8, 2024 @ 4:30 p.m. ET Domestic: 1-888-886-7786 International: 1-416-764-8658 Conference ID: 96934019 Webcast: Link About Arcturus

      4/25/24 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

      Kostaive® anticipated to launch in Japan this year ARCT-032 remains on track for Phase 1b interim data in Q2 ARCT-810 remains on track for Phase 2 interim data by the end of Q2 ARCT-2138 (Quadrivalent LUNAR-FLU) Phase 1 study for seasonal influenza vaccine initiated New STARR® vaccine discovery programs initiated for Lyme Disease and Gonorrhea Cash runway extended to Q1 2027 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its

      3/7/24 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcturus Therapeutics Holdings Inc. SEC Filings

    See more
    • SEC Form DEF 14A filed by Arcturus Therapeutics Holdings Inc.

      DEF 14A - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      4/25/25 5:15:29 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

      SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      4/25/25 6:18:10 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

      SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      4/23/25 8:14:38 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Arcturus Therapeutics Holdings Inc.

      10-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      3/6/25 4:39:12 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      3/6/25 4:02:38 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Arcturus Therapeutics Holdings Inc.

      SCHEDULE 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      2/5/25 7:52:19 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Arcturus Therapeutics Holdings Inc.

      10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      11/7/24 4:58:19 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      11/7/24 4:25:35 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Arcturus Therapeutics Holdings Inc.

      144 - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      10/15/24 4:29:01 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      8/13/24 7:54:14 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcturus Therapeutics Holdings Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea

      2/4/25 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

      Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm

      6/20/24 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Appoints John Markels, Ph.D. to its Board of Directors

      Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C

      12/13/22 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors

      PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, including rare diseases. Dr. Sutherland is a pulmonologist by training with deep clinical knowledge combined with R&D and corporate strategy leadership across pulmonary and rare diseases. In connection with

      1/18/22 7:00:00 AM ET
      $ARCT
      $KRYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Jing Marantz, M.D., Ph.D., M.B.A., an experienced biopharma industry executive, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005321/en/Jing L Marantz, M.D., Ph.D., M.B.A. (Photo: Business Wire) "We are very pleased to welcome Dr. Jing Marantz, to the Arcturus Board," said Joseph Payne, President &

      12/13/21 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcturus Therapeutics Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Legal Officer Kurata Lance

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:07:29 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Payne Joseph E

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:59 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer & COO Chivukula Pad

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:26 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Sassine Andy

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:07 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer & COO Chivukula Pad sold $249,121 worth of shares (12,000 units at $20.76), decreasing direct ownership by 3% to 435,334 units (SEC Form 4)

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      10/16/24 9:05:50 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Slaoui Moncef

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      6/21/24 9:30:44 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Slaoui Moncef

      3 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      6/21/24 9:30:17 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Marantz Jing L. converted options into 3,131 shares (SEC Form 4)

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      6/18/24 9:01:30 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Holmes Edward W converted options into 3,131 shares (SEC Form 4)

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      6/18/24 9:01:13 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Markels John converted options into 3,131 shares (SEC Form 4)

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      6/18/24 9:00:59 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcturus Therapeutics Holdings Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Arcturus Therapeutics with a new price target

      BTIG Research initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $41.00

      1/28/25 8:51:42 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Arcturus Therapeutics with a new price target

      Leerink Partners initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $70.00

      8/12/24 7:16:41 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Arcturus Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $90.00

      12/13/23 8:02:48 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Arcturus Therapeutics with a new price target

      William Blair initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $71.00

      7/24/23 7:46:14 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Arcturus Therapeutics from Neutral to Buy and set a new price target of $51.00 from $19.00 previously

      5/11/23 6:40:36 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Arcturus Therapeutics with a new price target

      Wells Fargo resumed coverage of Arcturus Therapeutics with a rating of Overweight and set a new price target of $35.00

      11/14/22 9:02:28 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Arcturus Therapeutics from Neutral to Underperform and set a new price target of $18.00

      11/10/22 7:20:41 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Arcturus Therapeutics from Neutral to Buy and set a new price target of $35.00 from $22.00 previously

      11/3/22 1:46:41 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics upgraded by Barclays with a new price target

      Barclays upgraded Arcturus Therapeutics from Underweight to Equal Weight and set a new price target of $25.00 from $16.00 previously

      11/2/22 9:12:54 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics downgraded by Raymond James

      Raymond James downgraded Arcturus Therapeutics from Mkt Perform to Underperform

      8/10/22 6:21:23 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcturus Therapeutics Holdings Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

      SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      11/8/24 3:17:24 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

      SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      11/5/24 6:07:26 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      4/5/24 12:18:33 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      2/13/24 4:59:02 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      2/12/24 6:09:45 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      2/5/24 6:08:57 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      1/29/24 4:01:01 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      1/25/24 1:48:50 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      1/25/24 7:48:41 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      1/17/24 2:43:10 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care